Introduction The objective of this study was to obtain parameter estimates for the efficacy of duloxetine versus alternative oral therapies for the treatment of chronic low back pain.
Introduction
Chronic low back pain (CLBP) is a disabling condition, defined as any pain in the low back that persists for at least 12 weeks [26, 27] . CLBP is one of the most common musculoskeletal disorders in developed countries, representing a large economic burden due to its deleterious effect on adults of working age [11] . Estimates for the prevalence of CLBP range from 1.0 to 58.1 % (mean 18.1 %; median 15.0 %) [18] .
CLBP is often progressive and characterised as a symptom unrelated to a specific diagnosis, making cause difficult to determine [12] . Due to its refractory nature, prognosis and response to therapy are poor, and the appropriate choice of treatment is less certain [6] , and aimed at symptom relief. Management strategies include the use of systemic or local pharmacological therapies [1] : non-scheduled opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), scheduled opioid analgesics, anticonvulsants, and antidepressants.
Duloxetine is a serotonin-norepinephrine reuptake inhibitor that acts by modulating the descending pain inhibitory pathways, under the hypothesis that this mode of action should work across all chronic pain states independent of the underlying pathology. In placebo-controlled phase III trials, excluding patients with limited medical radiography (LMR) and spinal stenosis duloxetine-treated patients with axial CLBP experienced reductions in pain and improvements in their physical functioning [28] [29] [30] . Two of these studies allowed concomitant NSAID use [28, 30] . However, duloxetine has not been compared in a head-to-head fashion with an active therapy for the treatment of CLBP.
The aim of this meta-analysis was to evaluate how the efficacy of available oral pharmacological therapies compared to duloxetine, by statistically pooling available data from randomised controlled trials (RCTs). As there were no head-to-head trials, an indirect comparison was chosen using placebo as the common comparator.
Materials and methods

Systematic literature review
A systematic review of the published literature, using PubMed, EMBASE, Cochrane and Centre for Reviews and Dissemination (CRD) databases, was conducted with the objective of identifying all potentially relevant evidence relating to the efficacy and safety of pharmacological therapies for the treatment of CLBP (Table 1) . A first review identified articles published between 1966 and 2008. An update to this review during January 2011 identified papers published from 2008 onwards. Internal study reports of all duloxetine trials were provided by the study sponsor, Eli Lilly and Company.
All aspects of the systematic literature review process (i.e. screening, data extraction and quality assessment) were undertaken by two independent reviewers for the purposes of verification, inclusive of dual entry into Microsoft Excel Ò . Any discrepancies and/or conflicts were arbitrated by a third reviewer. Titles, abstracts and keywords for all potentially relevant publications were screened based on pre-defined inclusion/exclusion criteria in accordance with the PICOS method. Those potentially eligible for inclusion in the meta-analysis were of English language, randomised, double-blind placebo-controlled trials among adults aged over 18 years, with a diagnosis of CLBP defined as having experienced pain for at least 3 months before entering the study. Studies were excluded included publications were extracted into a structured Excel workbook corresponding to distinct study outcomes of interest, including study design synopsis, comparator therapies, dosing regimen, titration schedule, duration of treatment, baseline characteristics (i.e. pain severity, age and sex), and efficacy outcomes [pain intensity measured on the visual analogue scale (VAS), numeric rating scale (NRS) or bodily pain index (BPI)]. The quality of each study was assessed using methodological checklist recommended by Cochrane for the critical appraisal of RCTs [33] . The checklist rates the quality of the methodology using a dichotomous scale, across seven different aspects of study design and reporting, such as the appropriateness and adequacy of reporting, randomisation and blinding methods, whether the type of analysis conducted was from an intention-to-treat principle, and if any imbalances were accounted for. The assessment also contains a concluding critique as to the extent to which study design and baseline characteristics influenced study outcomes. A feasibility assessment was conducted to assess the level of heterogeneity between studies on the basis of patient characteristics, study characteristics and study outcomes available for generating pooled efficacy estimates, using a narrative approach. Overall, the number of interventions investigated across the clinical trials was high and the form of treatment administration differed across studies, thereby leading to various placebos being used. Time horizons also varied markedly across studies. The final list of studies eligible for the meta-analysis was validated on the basis of clinical relevance, based on expert opinion. These studies evaluated oral treatments through parallel-group design, with a length of treatment between 8 and 12 weeks, and reported a pain intensity measure.
Evaluation
To address the issue of heterogeneity between pain intensity scales, standardised mean difference (SMD) in change from baseline relative to placebo was used as a summary statistic, as recommended by the 2011 Cochrane Handbook [16] , whereby a negative value demonstrates a better outcome than the comparator. To avoid bias in the effect size, SMD was defined as Hedges adjusted g(g*) [15] .
When the change from baseline in each treatment group was not provided, the SMD was approximated as the mean difference of final values divided by the estimated standard deviation of change from baseline [16] .
Meta-analysis
The meta-analysis was conducted according to a prespecified analysis plan. The network included all labelled doses of oral treatments documented in the systematic literature review. Treatments were grouped according to their respective class [cyclooxygenase-2 (cox-2) inhibitors, scheduled opioids, non-scheduled opioids, selective serotonin reuptake inhibitors (SSRIs), and other (glucosamine)] due to the low number of studies available for the analysis. Due to the absence of head-to-head trials, duloxetine was compared to the other active treatments through indirect comparison using placebo as a common comparator. Fixed and random effects normal models provided estimates of the mean difference in treatment effect. To handle three-arm trials and the assumption of independence between pair-wise comparisons, hierarchical models were run in a Bayesian framework using Markov Chain Monte Carlo (MCMC) simulation in the WinBugs software [31] .
Pooled estimates of treatment difference in three-arm trials were used to calculate Cochrane Q tests, I
2 and s 2 statistics to test and quantify between-study heterogeneity [17] . Forest plots were generated to visually assess the extent of heterogeneity. Sources of heterogeneity were explored through meta-regression analysis. Baseline pain score, score at screening, mean age, and sex (defined as the proportion of females in the study population), pain duration (dichotomous variable, C6 months of pain before baseline) and enriched enrolment design (i.e. exclusion of non-responders following exposure to study drug) were included in univariate meta-regressions. In studies with enriched enrolment design, it was hypothesised that baseline score could be higher than the true baseline severity of the population due to the exclusion of non-responders [32] . Therefore, score at screening, preceding the open-label treatment phase, was also tested. A uniform prior distribution (Uniform [0, 2]) was applied to the between-study variance parameter in the base-case analysis. A uniform distribution (Uniform [0, 2]) for the prior between-study standard deviation and a gamma distribution (Gamma [0.01, 100]) for the prior precision were tested in sensitivity analysis. Additional analyses limited to trial arms corresponding to the most prevalent dosing regimens in the UK, as well as highquality studies (with an overall rating of [6), were carried out. Figure 1 displays the results of the literature search, screening, review and study selection. Sixty-two studies potentially eligible for inclusion in the meta-analysis were identified from 1,881 references screened; 15 were finally included, representing 5,374 patients. All trials compared active treatment to placebo (Fig. 2) . Table 2 describes the population characteristics of the included studies.
Results
Literature search
Treatment study periods ranged from 8 weeks to 1 year. Of note, all scheduled and non-scheduled opioids, and cox-2 inhibitor trials were either of enriched enrolment or flare design. Flare design was defined as trials only inclusive of Nine studies included titration periods and four included enriched enrolment periods (three of which compared scheduled opioids to placebo). Concomitant analgesic use was allowed in five studies. The results of the quality assessment showed that the majority of studies (60 %) achieved a rating of greater than 6 (Table 3) . Three studies (20 %) rated 7 on 7; one of which was the duloxetine trial [30] comparing duloxetine 60 mg to placebo. The other two duloxetine trials [28, 29] were among those scoring 6 on 7.
Meta-analysis
Primary analysis: total population Standardised mean differences for each study are reported in Table 4 . Figure 3 illustrates the estimated SMDs of study treatments against placebo with their 95 % confidence intervals (CI), as well as the pooled Bayesian fixed and random effect estimates by drug class. With the exception of four studies [7, 29, 34, 36] , all reported at least a small magnitude of effect according to the American guideline definition of magnitude of effect [4] [14] [SMD = -0.9(Var = 0.03)]. Substantial heterogeneity was observed within the subgroups of studies comparing non-scheduled opioids to placebo (I 2 = 75 %) and scheduled opioids to placebo (I 2 = 79 %). The estimated heterogeneity was very low for all other drug classes.
The base-case meta-analysis results (Fig. 3) showed that in the fixed effects model, with the exception of SSRIs and glucosamine, all drug classes were more effective than placebo. The indirect comparison (Table 5 ) demonstrated that scheduled opioids were more effective than duloxetine, although the estimated SMD was less than small [|SMD| \ 0.2; SMD = -0.15 (95 % credibility interval, CrI -0.29, -0.01)]. No difference was shown between duloxetine and non-scheduled opioids, cox-2 inhibitors, SSRIs, or glucosamine as their respective credibility intervals included zero. The random effects model provided a better fit (deviance information criterion, DIC = -17.9 versus 4.7 for the fixed effects model) and led to a similar interpretation to that of the fixed effects model. The estimated between-study variance was very low (s 2 = 0.04). There was no difference between duloxetine and all of the other drug classes.
Sources of heterogeneity were explored through metaregression analysis. In a univariate analysis (Table 6 ), only pain duration was found to be associated with treatment effect. Studies in which patients had suffered pain for more than 6 months had lower treatment differences.
Sensitivity analysis: NSAID non-users, prior distributions, most prevalent dosing regimen and high-quality studies Sensitivity analyses results for the random effects model are reported in Table 7 . The first sensitivity analysis focussed on duloxetine monotherapy (i.e. excluding those with concomitant NSAID use) and was conducted using results from a pre-specified sub-group of patients from the duloxetine trials. Studies by Dickens [7] and Wilkens et al. [36] were excluded from this analysis as they allowed concomitant NSAID use. No drug class was found to be more effective than duloxetine. This was also true for the fixed effects model. In a second sensitivity analysis, the random effects model (including all studies) was robust to the prior distribution assigned to the between-study variance. Tramadol 300 mg [34] , etoricoxib 90 mg [2, 22] , duloxetine 120 mg and oxycodone ? naltrexone qid were excluded from the sensitivity analysis focusing on the most prevalent dose. Another analysis excluded studies with overall quality ratings below 6. These lead to the same conclusions as the base-case analysis.
Discussion
The objective of this study was to conduct an indirect comparison of the efficacy of duloxetine relative to alternative oral pharmacological therapies in the treatment of CLBP, in the absence of direct evidence. Fifteen studies evaluating oral treatments for CLBP were included in a meta-analysis. The overall quality of the included studies was high. The base-case fixed effects model showed a difference between scheduled opioids and duloxetine, although the estimated magnitude of effect was less than small (|SMD| \ 0.2). However, no difference was found for the random effects model, which provided a better fit. Although sensitivity analyses showed slight variations in parameter estimates, the results led to the same conclusions as demonstrated in the base-case analyses. Meta-regression analyses did not provide any conclusive insight into observed variability; with the exception of pain duration, no covariate was found to be associated with treatment effect. The effect of pain duration was not explored further as it was not deemed clinically relevant as a dichotomous variable.
Limitations of the present study include the low number of studies available for inclusion in the analysis, considering the high number of comparators included within the network. The meta-analysis feasibility study concluded that strict inclusion criteria were necessary to obtain a subset of studies sufficiently homogeneous for pooling. One study was excluded as it was open-label, seven studies had crossover designs and the 8-week minimum treatment duration cut-off inclusion criteria resulted in the exclusion of ten studies. The comparison of SSRIs to placebo was only based on one study. The low number of studies resulted in difficulties distinguishing spurious variability from heterogeneity due to study characteristics. Furthermore, it was not possible to assess the overall influence of study design on treatment effect, as three of the four studies with an enriched enrolment phase evaluated the effect of scheduled opioid use. The power to identify significant effects for baseline study characteristics was low, due to the low number of studies available. For example, although baseline severity is thought to have a clinical impact, it was not found to be associated with treatment effect. Therefore, the analysis would benefit from further research as studies become available. It was also not possible to accurately investigate publication bias due to the low number of studies by treatment category.
Another limitation was the different outcome measures reported. The use of a standardised measure (i.e. SMD), which is more difficult to interpret than a clinical measure, CrI credibility interval, SE (SMD) standard error of standardised mean difference, SMD standardised mean difference Eur Spine J (2013) 22:1996-2009 2007 was deemed necessary to handle the different scales (VAS, BPI and NRS). Differences were also observed in the reporting of outcomes (e.g. change from baseline, difference between treatment arms, mean values at baseline and endpoint) which made the use of assumptions necessary to suitably derive SMDs. As in Machado et al. [20] , the efficacy of treatments was only compared using pain intensity outcomes, which may not fully reflect the potential benefits of treatments in terms of function and quality of life.
To the best of our knowledge, following publications by Machado et al. [20] and Moore et al. [21] analysing direct evidence of analgesic effects of treatments for non-specific low back pain, this is the first attempt at an indirect comparison of the clinical evidence for the treatment of chronic lower back pain. Although Moore et al. [21] questioned the feasibility of an indirect comparison in CLBP, and while the number of eligible studies was small, we believe this study provides useful insight into the relative efficacy of treatments using pain intensity scales. Similar to diabetic peripheral neuropathic pain [24] and fibromyalgia [5] , the available evidence shows that there does not seem to be any difference in efficacy between duloxetine and other oral pharmacological therapies for CLBP.
